Na+ channels and Ca2+ channels of the cell membrane as targets of neuroprotective substances

Advances in Experimental Medicine and Biology

Volumn 513, Issue , 2002, Pages 161-181

  Alzheimer, Christian ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIZOCILPINE; FOSPHENYTOIN SODIUM; LAMOTRIGINE; LIFARIZINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NIFEDIPINE; OMEGA CONOTOXIN MVIIA; PHENYTOIN; RILUZOLE; SB 201823; SB 201823A; SB 206284; SIPATRIGINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TETRODOTOXIN; UNCLASSIFIED DRUG; CALCIUM; SODIUM;

BRAIN INJURY; BRAIN ISCHEMIA; CELL MEMBRANE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HOMEOSTASIS; HUMAN; META ANALYSIS; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SODIUM CURRENT; STROKE; ANIMAL; BRAIN; CYTOLOGY; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; BRAIN; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; SODIUM; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 0036935635     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (97)

1. Friedman JE, Haddad GG. Removal of extracellular sodium prevents anoxia-induced injury in freshly dissociated rat CA1 hippocampal neurons. Brain Res 1994; 641:57-64.
2. Martin RL, Lloyd HG, Cowan AI. The early events of oxygen and glucose deprivation: Setting the scene for neuronal death? Trends Neurosci 1994; 17:251-257.
3. Taylor CP, Weber ML, Gaughan CL, Lehning EJ, LoPachin RM. Oxygen/glucose deprivation in hippocampal slices: Altered intraneuronal elemental composition predicts structural and functional damage. J Neurosci 1999; 19:619-629.
4. Zhang Y, Lipton P. Cytosolic Ca2+ changes during in vitro ischemia in rat hippocampal slices: major roles for glutamate and Na+-dependent Ca2+ release from mitochondria. J Neurosci 1999; 19:3307-3315.
5. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 2000; 403:316-321.
6. Leao. Further observations on the spreading depression of activity in the cerebral cortex. J Neurophysiol 1947; 10:409-414.
7. Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression- like depolarization. Physiol Rev 2001; 81:1065-1096.
8. + channels in ion fluxes during hypoxia of rat hippocampal slices. J Neurophysiol 2000; 84:1869-1880.
9. Yamamoto S, Tanaka E, Higashi H. Mediation by intracellular calcium-dependent signals of hypoxic hyperpolarization in rat hippocampal CA1 neurons in vitro. J Neurophysiol 1997; 77:386-392.
10. + channels. Trends Neurosci 2001; 24:339-346.
11. LoPachin RM. Intraneuronal ion distribution during experimental oxygen/glucose deprivation. Routes of ion flux as targets of neuroprotective strategies. Ann NY Acad Sci 1999; 890:191-203.
12. Crill WE. Persistent sodium current in mammalian central neurons. Annu Rev Physiol 1996; 58:349-362.
13. Stafstrom CE, Schwindt PC, Crill WE. Negative slope conductance due to a persistent subthreshold sodium current in cat neocortical neurons in vitro. Brain Res 1982; 236:221-226.
14. Stafstrom CE, Schwindt PC, Chubb MC, Crill WE. Properties of persistent sodium conductance and calcium conductance of layer V neurons from cat sensorimotor cortex in vitro. J Neurophysiol 1985; 53:153-170.
15. Connors BW, Gutnick MJ, Prince DA. Electrophysiological properties of neocortical neurons in vitro. J Neurophysiol 1982; 48:1302-1320.
16. + current in pyramidal neurons from rat sensorimotor cortex. J Neurophysiol 1993; 69:290-292.
17. Fleidervish IA, Gutnick MJ. Kinetics of slow inactivation of persistent sodium current in layer V neurons of mouse neocortical slices. J Neurophysiol 1996; 76:2125-2130.
18. French CR, Sah P, Buckett KJ, Gage PW. A voltage-dependent persistent sodium current in mammalian hippocampal neurons. J Gen Physiol 1990; 95:1139-1157.
19. +-dependent theta-like rhythmicity in stellate cells of entorhinal cortex layer II. Nature 1989; 342:175-177.
20. Magistretti J, Alonso A. Biophysical properties and slow voltage-dependent inactivation of a sustained sodium current in entorhinal cortex layer-II principal neurons: A whole-cell and single-channel study. J Gen Physiol 1999; 114:491-509.
21. Agrawal N, Hamam BN, Magistretti J, Alonso A, Ragsdale DS. Persistent sodium channel activity mediates subthreshold membrane potential oscillations and low-threshold spikes in rat entorhinal cortex layer V neurons. Neuroscience 2001; 102:53-64.
22. Jahnsen H, Llinas R. Ionic basis for the electro-responsiveness and oscillatory properties of guinea-pig thalamic neurones in vitro. J Physiol (Lond) 1984; 349:227-247.
23. Parri HR, Crunelli V. Sodium current in rat and cat thalamocortical neurons: Role of a noninactivating component in tonic and burst firing. J Neurosci 1998; 18:854-867.
24. + current? J Neurophysiol 1995; 74:934-941.
25. + conductance in mediumsized neostriatal neurons: Characterization using infrared videomicroscopy and whole cell patch- clamp recordings. J Neurophysiol 1995; 74:1343-1348.
26. Llinas R, Sugimori M. Electrophysiological properties of in vitro Purkinje cell somata in mammalian cerebellar slices. J Physiol (Lond)1980; 305:171-195.
27. Kay AR, Sugimori M, Llinas R. Kinetic and stochastic properties of a persistent sodium current in mature guinea pig cerebellar Purkinje cells. J Neurophysiol 1998; 80:1167-1179.
28. + currents that fail to inactivate. Trends Neurosci 1993; 16:455-460.
29. Brown AM, Schwindt PC, Crill WE. Voltage dependence and activation kinetics of pharmacologically defined components of the high-threshold calcium current in rat neocortical neurons. J Neurophysiol 1993; 70:1530-1543.
30. + current in pyramidal neurons from rat and cat sensorimotor cortex. J Neurosci 1993; 13:660-673.
31. + current in entorhinal cortex neurons. J Neurosci 1999; 19:7334-7341.
32. Catterall WA. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron 2000; 26:13-25.
33. Hammarstrom AK, Gage PW. Inhibition of oxidative metabolism increases persistent sodium current in rat CA1 hippocampal neurons. J Physiol (Lond) 1998; 510 (Pt 3):735-741.
34. Hammarstrom AK, Gage PW. Nitric oxide increases persistent sodium current in rat hippocampal neurons. J Physiol (Lond) 1999; 520 Pt 2:451-461.
35. Hammarstrom AK, Gage PW. Oxygen-sensing persistent sodium channels in rat hippocampus. J Physiol (Lond) 2000; 529 (Pt 1):107-118.
36. Horn EM, Waldrop TG. Hypoxic augmentation of fast-inactivating and persistent sodium currents in rat caudal hypothalamic neurons. J Neurophysiol 2000; 84:2572-2581.
37. Somjen GG, Muller M. Potassium-induced enhancement of persistent inward current in hippocampal neurons in isolation and in tissue slices. Brain Res 2000; 885:102-110.
38. Fleidervish IA, Gebhardt C, Astman N, Gutnick M J, Heinemann U. Enhanced spontaneous transmitter release is the earliest consequence of neocortical hypoxia that can explain the disruption of normal circuit function. J Neurosci 2001; 21:4600-4608.
39. + current in rat hippocampal neurones via protein kinase C. J Physiol (Lond) 1997; 503 (Pt 3):479-488.
40. Alroy G, Su H, Yaari Y. Protein kinase C mediates muscarinic block of intrinsic bursting in rat hippocampal neurons. J Physiol (Lond) 1999; 518 (Pt 1):71-79.
41. Kuo CC, Bean BP. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. Mol Pharmacol 1994; 46:716-725.
42. Quandt FN. Modification of slow inactivation of single sodium channels by phenytoin in neuroblastoma cells. Mol Pharmacol 1988; 34:557-565.
43. + channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol Pharmacol 1991; 40:756-765.
44. + current of mammalian CNS neurones. NeuroReport 1995; 6:1778-1780.
45. Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol 1997; 77:3021-3034.
46. Malgouris C, Bardot F, Daniel M, Pellis F, Rataud J, Uzan A et al. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989; 9:3720-3727.
47. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994; 45:1055-1060.
48. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pfl gers Arch 1991; 419:603-609.
49. Urbani A, Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 2000; 12:3567-3574.
50. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250:473-476.
51. Prakriya M, Mennerick S. Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 2000; 26:671-682.
52. Weber ML, Taylor CP. Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials. Brain Res 1994; 664:167-177.
53. + channels as targets for neuroprotective drugs. Trends Pharmacol Sci 1995; 16:309-316.
54. McGivern JG, Patmore L, Sheridan RD. Actions of the novel neuroprotective agent, lifarizine (RS-87476), on voltage-dependent sodium currents in the neuroblastoma cell line, N1E-115. Br J Pharmacol 1995; 114:1738-1744.
55. + channels in rat hippocampal neurones. Pfl gers Arch 1995; 430:437-446.
56. + channels. Neuroscience 1996; 73:951-962.
57. Obrenovitch TP. Sodium and potassium channel modulators: their role in neuroprotection. Int Rev Nenrobiol 1997; 40:109-135.
58. +-channel clown-modulation versus presynaptic glutamate release inhibition. Rev Neurosci 1998; 9:203-211.
59. + channels: A rational and effective strategy against ischemic drain damage. Pharmacol Rev 1996; 48:21-67.
60. Lynch JJ, III, Yu SP, Canzoniero LM, Sensi SL, Choi DW. Sodium channel blockers reduce oxygen-glucose deprivation-induced cortical neuronal injury when combined with glutamate receptor antagonists. J Pharmacol Exp Ther 1995; 273:554-560.
61. + homeostasis protects organotypic hippocampal slice cultures from hypoxic/hypoglycemic injury. Neuropharmacology 2000; 39:1779-1787.
62. Tasker RC, Coyle JT, Vornov JJ. The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: Protection by early tetrodotoxin or delayed MK-801. J Neurosci 1992; 12:4298-4308.
63. Watson GB, Lanthorn TH. Phenytoin delays ischemic depolarization, but cannot block its long- term consequences, in the rat hippocampal slice. Neuropharmacology 1995; 34:553-558.
64. Amagasa M, Mizoi K, Ogawa A, Yoshimoto T. Actions of brain-protecting substances against both oxygen and glucose deprivation in the guinea pig hippocampal neurons studied in vitro. Brain Res 1989; 504:87-93.
65. Stanton PK, Moskal JR. Diphenylhydantoin protects against hypoxia-induced impairment of hippocampal synaptic transmission. Brain Res 1991; 546:351-354.
66. Taft WC, Clifton GL, Blair RE, DeLorenzo RJ. Phenytoin protects against ischemia-produced neuronal cell death. Brain Res 1989; 483:143-148.
67. Rataud J, Debarnot F, Mary V, Pratt J, Stutzmann JM. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994; 172:19-23.
68. Boxer PA, Cordon JJ, Mann ME, Rodolosi LC, Vartanian MG, Rock DM et al. Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. Stroke 1990; 21:III47-III51.
69. Pratt J, Rataud J, Bardot F, Roux M, Blanchard JC, Laduron PM et al. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett 1992; 140:225-230.
70. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993; 24:1063-1067.
71. Sun FY, Faden AI. Neuroprotective effects of 619C89, a use-dependent sodium channel blocker, in rat traumatic brain injury. Brain Res 1995; 673:133-140.
72. Okiyama K, Smith DH, Gennarelli TA, Simon RP, Leach M, McIntosh TK. The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J Neurochem 1995; 64:802-809.
73. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26:117-121.
74. + conductance in rat optic nerve axons. Proc Natl Acad Sci USA 1993; 90:6976-6980.
75. Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. Efficacy and tolerability of lifarizine in acute ischemic stroke. A pilot study. Lifarizine Study Group. Ann NY Acad Sci 1995; 765:317-318.
76. Muir KW, Holzapfel L, Lees KR. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc Dis 2000; 10:431-436.
77. Choi DW. Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988; 11:465-469.
78. Mattson MP. Calcium and free radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Perspect Dev Neurobiol 1996; 3:79-91.
79. Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma 1997; 14:23-34.
80. Hunter AJ. Calcium antagonists: Their role in neuroprotection. Int Rev Neurobiol 1997; 40:95-108.
81. Scriabine A. Calcium channel antagonists as neuroprotective agents. In: B r PR, Flint Beal M, eds. Neuroprotection in CNS Diseases. New York: Marcel Dekker Inc., 1997:27-51.
82. 2+ channel antagonists and neuroprotection from cerebral ischemia. Eur J Pharmacol 1998; 363:1-15.
83. Horn J, Limburg M. Calcium antagonists for ischemic stroke: A systematic review. Stroke 2001; 32:570-576.
84. 2+ channels. Annu Rev Cell Dev Biol 2000; 16:521-555.
85. Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E et al. Nomenclature of voltage-gated calcium channels. Neuron 2000; 25:533-535.
86. 2+ channels and pharmacological blockade: Potential pathophysiological relevance. Cardiovasc Drugs Ther 1997; 11:723-739.
87. Sayer RJ, Brown AM, Schwindt PC, Crill WE. Calcium currents in acutely isolated human neocortical neurons. J Neurophysiol 1993; 69:1596-1606.
88. 2+ channels at the base of major dendrites in hippocampal pyramidal neurons. Nature 1990; 347:281-284.
89. Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron 1992; 9:1099-1115.
90. 2+ channels are located on somata, dendrites, and a subpopulation of dendritic spines on live hippocampal pyramidal neurons. J Neurosci 1994; 14:6815-6824.
91. Pringle AK, Benham CD, Sim L, Kennedy J, Iannotti F, Sundstrom LE. Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. Stroke 1996; 27:2124-2130.
92. Valentino K, Newcomb R, Gadbois T, Singh T, Bowersox S, Bitner S et al. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci USA 1993; 90:7894-7897.
93. 2+-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab 1994; 14:903-910.
94. Takizawa S, Matsushima K, Fujita H, Nanri K, Ogawa S, Shinohara Y. A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia. J Cereb Blood Flow Metab 1995; 15:611-618.
95. Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP. Mitochondrial dysfunction after experimental and human brain injury and its possible reversal with a selective N-type calcium channel antagonist (SNX-111). Neurol Res 1997; 19:334-339.
96. Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP. Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: Dose-response and time-window profiles for administration of the calcium channel blocker Ziconotide in experimental brain injury. J Neurosurg 2000; 93:829-834.
97. Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: Structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 1995; 35:707-734.